Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 7, 2026, 9:25 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 413 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Food Effect in Healthy Participants Clear all

Conditions: Healthy
Interventions: JTK-853 or Placebo; Drug
Lead sponsor: Akros Pharma Inc.; Industry
Eligibility: 18 Years to 45 Years · Male only
Enrollment: 70 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Pharmacokinetics
Interventions: midomafetamine; Drug
Lead sponsor: Resilient Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Knoxville, Tennessee

Conditions: Healthy Volunteers
Interventions: PF614, Naltrexone Hydrochloride, OxyContin; Drug
Lead sponsor: Ensysce Biosciences; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 84 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Healthy Volunteers
Interventions: TAK-906; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 55 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Healthy Volunteers
Interventions: Venglustat; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 9 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 1
States / cities: Saint Paul, Minnesota

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: Danirixin, Omeprazole; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 65 Years to 80 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Healthy
Interventions: Oxycodone; Drug
Lead sponsor: Pain Therapeutics; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 34 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 2
States / cities: Overland Park, Kansas

Conditions: Healthy
Interventions: Palbociclib administered Fasted, Palbociclib administered Fed high calorie, Palbociclib administered Fed low calorie, Palbociclib administered Fed moderate calorie; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Healthy Volunteers
Interventions: CC-92480, Placebo; Drug · Other
Lead sponsor: Celgene; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Gonorrhea
Interventions: Zoliflodacin, high calorie, high fat breakfast; Drug · Other
Lead sponsor: Drugs for Neglected Diseases; Other
Eligibility: 18 Years to 55 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Healthy Volunteers
Interventions: Lenalidomide; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: Daytona Beach, Florida

Conditions: Dietary Fats, Pharmacokinetics
Interventions: Regorafenib (Stivarga, BAY73-4506); Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years to 45 Years · Male only
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Brighton, Massachusetts

Conditions: Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis
Interventions: CCX168; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Healthy
Interventions: TP-05 (lotilaner oral), fasted group, TP-05 (lotilaner oral), high-fat group, TP-05 (lotilaner oral), low-fat group; Drug
Lead sponsor: Tarsus Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 59 Years
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Dermatitis, Atopic
Interventions: P3-Fast, Comm-Fast, Vari-Fast, Comm-Fed; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 46 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Healthy Volunteers
Interventions: PF-04449913, ketoconazole; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: HIV Infections
Interventions: VH4524184, Itraconazole, Rifabutin, Phenytoin, Metformin, Digoxin; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 126 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 2
States / cities: Lenexa, Kansas • Salt Lake City, Utah

Conditions: Healthy Volunteer
Interventions: CC-92480; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 56 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Daytona Beach, Florida

Conditions: Presumptive NAFLD
Interventions: EDP 305, Placebo; Drug
Lead sponsor: Enanta Pharmaceuticals, Inc; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 146 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Lenexa, Kansas

Conditions: Influenza
Interventions: Placebo for VNT-101, VNT-101; Other · Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 59 Years
Enrollment: 78 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Healthy
Interventions: vadadustat; Drug
Lead sponsor: Akebia Therapeutics; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 54 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: IPF
Interventions: HNC1058 Capsules; Drug
Lead sponsor: Guangzhou Henovcom Bioscience Co. Ltd.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Arthritis
Interventions: PN400; Drug
Lead sponsor: POZEN; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Healthy Volunteers
Interventions: Deflazacort; Drug
Lead sponsor: PTC Therapeutics; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 45 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: San Antonio, Texas

Search by objective public record fields.

Safety, Tolerability and Pharmacokinetics Study Assessing Ascending Single Oral JTK-853 Doses in Healthy Subjects

Food Effects on Bioavailability of MDMA in Healthy Volunteers

Evaluation of Oral PF614 Relative to OxyContin (PF614-102)

Bioavailability and Food Effect Study of Two Formulations of TAK-906

A Study of the Safety, Tolerability, and Bioavailability of Orally Administered Venglustat in Healthy Adult Participants

GSK1325756 Relative Bioavailability Study in Healthy Elderly Subjects

Effects of Food on Oxycodone Pharmacokinetics in Healthy Volunteers

Characterization Of The Effect Of Food On Palbociclib (PD-0332991) Absorption

A Study to Assess Safety, Tolerability, and Pharmacokinetics of CC-92480 Formulations in Healthy Adult Participants

Study to Investigate Effect of Food and Safety of a New Formulation of Zoliflodacin

Study to Evaluatethe Bioavailability and Food Effect Lenalidomide as an Oral Suspension

The Effect of Food (High Fat and Low Fat Breakfast) on the Pharmacokinetics of Regorafenib

A Study in Healthy Volunteers to Evaluate the Pharmacokinetic Food Effect and Cardiac Safety of CCX168

Study to Evaluate the Food Effect of TP-05 in Healthy Participants

Study of Commercial and Phase 3 of PF-04965842 Formulations, Estimation of Effect of Food on Commercial Formulation

Study To Determine The Effect Of Food And Strong CYP3A4 Enzyme Inhibitor On PF-04449913 Drug Levels

A Study to Evaluate VH4524184 Tablet Absorption, Effects of Food, and Interactions With Other Drugs in Healthy Adults

Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Food Effect of Single Ascending Doses of CC-92480 in Healthy Subjects

A Study of EDP 305 in Healthy Subjects and Subjects With Presumptive NAFLD

First-in-Human Study of VNT-101: Safety, Tolerability, and Pharmacokinetics

A Study in Evaluating Bioequivalence of Test and Reference Vadadustat 450 MG and 150 MG Tablets and to Determine Food Effect on the 450 MG Tablet

A Study to Evaluate the Safety, Tolerability, PK and PD of HNC1058

Study Evaluating the Effect of Food on the Bioavailability of PN400 Components

Food Effect and Bioavailability of Deflazacort Formulations in Healthy Volunteers